Adaptogens stimulate neuropeptidey and Hsp72 expression and release in neuroglia cells

Frontiers in Neuroscience

Volumn , Issue FEB, 2012, Pages

  Panossian, Alexander ^a   Wikman, Georg ^a   Kaur, Punit ^b   Asea, Alexzander ^b  

^a Swedish Herbal Institute   (Sweden)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Adapt 232; Adaptogen; Eleutherococcus senticosus; Heat shock proteins; Neuropeptide Y; Rhodiola rosea; Salidroside; Schisandra chinensis

Indexed keywords

ADAPT 232; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; HEAT SHOCK PROTEIN 72; NEUROPEPTIDE Y; RHODIOLA ROSEA EXTRACT; SALIDROSIDE; SCHISANDRA CHINENSIS EXTRACT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADAPTATION; ARTICLE; AUTOCRINE EFFECT; BERRY; CELL STRESS; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GLIA CELL; HUMAN; HUMAN CELL; PLANT ROOT; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 84862186276     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2012.00006     Document Type: Article

References (78)

1. Abe, K., Kuo, L., and Zukowska, Z. (2010). Neuropeptide Y is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition. Exp. Biol. Med. (Maywood) 235, 1179-1184.
2. Antonijevic, I. A., Murck, H., Bohlhal-ter, S., Frieboes, R. M., Holsboer, F., and Steiger, A. (2000). Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 39, 1474-1481.
3. Asea, A. (2006). Initiation of the immune response by extracellular Hsp72: chaperokine activity of Hsp72. Curr. Immunol. Rev. 2, 209-215.
4. Asea, A. (2007). "Release of heat shock proteins: passive vs active release mechanisms," in Potent Mediators of Inflammation and Immunity, eds A. Asea and S. K. Calderwood (Dordrecht: Springer), 3-20.
5. Asea, A. (2003). Chaperokine-induced signal transduction pathways. Exerc. Immunol. Rev. 9, 25-33.
6. Asea, A. (2008). Hsp70: a chap-erokine. Novartis Found. Symp. 291, 173-179; discussion 179-183, 221-174.
7. Asea, A., and Brown, I. R. (2008). Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection. Dordrecht: Springer Science.
8. Aslanyan, G., Amroyan, E., Gabrielyan, E., Nylander, M., Wikman, G., and Panossian, A. (2010). Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions. Phytomedicine 17, 494-499.
9. Billington, C. J., Briggs, J. E., Harker, S., Grace, M., and Levine, A. S. (1994). Neuropeptide Y in hypothal-amic paraventricular nucleus: a center coordinating energy metabolism. Am. J. Physiol. 266, R1765-R1770.
10. Bogatova, R., Shlyakova, L., Salnitsky, V., and Wikman, G. (1997). Evaluation of the effect of single take of a phytoadaptogen on human subject work ability during long isolation. Aerospace Environ. Med. 31, 51-54.
11. Boulenger, J. P., Jerabek, I., Jolicoeur, F. B., Lavallee, Y. J., Leduc, R., and Cadieux, A. (1996). Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am. J. Psychiatry 153, 114-116.
12. Brekhman, I. I., and Dardymov, I. V. (1969). New substances of plant origin which increase nonspecific resistance. Annu. Rev. Pharmacol. 9, 419-430.
13. Bystritsky, A., Kerwin, L., and Feusner, J. D. (2008). A pilot study of Rho-diola rosea (Rhodax) for generalized anxiety disorder (GAD). J. Altern. Complement. Med. 14, 175-180.
14. Calderwood, S. K., Murshid, A., and Prince, T. (2009). The shock of aging: molecular chaperones and the heat shock response in longevity and aging a mini-review. Gerontology 55, 550-558.
15. Canto Soler, M. V., Gallo, J. E., Dodds, R. A., Hokfelt, T., Villar, M. J., and Suburo, A. M. (2002). Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina. Glia 39, 320-324.
16. Chiu, P. Y., and Ko, K. M. (2004). Schisandrin B protects myocar-dial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Mol. Cell. Biochem. 266, 139-144.
17. Cifani, C., Micioni Di, B. M., Vitale, G., Ruggieri, V., Ciccocioppo, R., and Massi, M. (2010). Effect of salidro-side, active principle of Rhodiola rosea extract, on binge eating. Phys-iol. Behav. 101, 555-562.
18. Crofford, L. J., Engleberg, N. C., and Demitrack, M. A. (1996). Neurohor-monal perturbations in fibromyal-gia. Baillieres Clin. Rheumatol. 10, 365-378.
19. Darbinyan, V., Aslanyan, G., Amroyan, E., Gabrielyan, E., Malmstrom, C., and Panossian, A. (2007). Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord. J. Psychiatry 61, 343-348.
20. Di Franco, M., Iannuccelli, C., Alessan-dri, C., Paradiso, M., Riccieri, V., Libri, F., and Valesini, G. (2009). Autonomic dysfunction and neu-ropeptide Y in fibromyalgia. Clin. Exp. Rheumatol. 27, S75-S78.
21. Du, M., Butchi, N. B., Woods, T., Morgan, T. W., and Peterson, K. E. (2010). Neuropeptide Y has a protective role during murine retrovirus-induced neurological disease. J. Virol. 84, 11076-11088.
22. Dumont, Y., Fournier, A., St-Pierre, S., and Quirion, R. (1993). Comparative characterization and autoradi-ographic distribution of neuropep-tide Y receptor subtypes in the rat brain. J. Neurosci. 13, 73-86.
23. Ferreira, R., Xapelli, S., Santos, T., Silva, A. P., Cristovao, A., Cortes, L., and Malva, J. O. (2010). Neuropep-tide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J. Biol. Chem. 285, 41921-41934.
24. Fletcher, M. A., Rosenthal, M., Antoni, M., Ironson, G., Zeng, X. R., Barnes, Z., Harvey, J. M., Hurwitz, B., Levis, S., Broderick, G., and Klimas, N. G. (2010). Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav. Brain Funct. 6, 76.
25. Hashimoto, R., Udagawa, J., Kagohashi, Y., Matsumoto, A., Hatta, T., and Otani, H. (2011). Direct and indirect effects of neuropeptide Y and neurotrophin 3 on myelination in the neonatal brains. Brain Res. 1373, 55-66.
26. Hecker, J. G., and McGarvey, M. (2011). Heat shock proteins as biomark-ers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair. Cell Stress Chaperones 16, 119-131.
27. Heilig, M., Wahlestedt, C., Ekman, R., and Widerlov, E. (1988). Antide-pressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur. J. Pharmacol. 147, 465-467.
28. Himmerich, H., Schonknecht, P., Heit-mann, S., and Sheldrick, A. J. (2010). Laboratory parameters and appetite regulators in patients with anorexia nervosa. J. Psychiatr. Pract. 16, 82-92.
29. Irwin, M. R. (2008). Human psy-choneuroimmunology: 20 years of discovery. Brain Behav. Immun. 22, 129-139.
30. Karamouzis, I., Karamouzis, M., Vrabas, I. S., Christoulas, K., Kyriazis, N., Giannoulis, E., and Mandroukas, K. (2002). The effects of marathon swimming on serum leptin and plasma neuropeptide Y levels. Clin. Chem. Lab. Med. 40, 132-136.
31. Kellogg, D. L. Jr. (2006). In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J. Appl. Physiol. 100, 1709-1718.
32. Kempna, P., Korner, M., Waser, B., Hofer, G., Nuoffer, J. M., Reubi, J. C., and Fluck, C. E. (2010). Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol. Cell. Endocrinol. 314, 101-109.
33. Kmiec, Z. (2006). Central regulation of food intake in ageing. J. Physiol. Pharmacol. 57(Suppl. 6), 7-16.
34. Kuo, L. E., Abe, K., and Zukowska, Z. (2007). Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides 28, 435-440.
35. Labelle, M., St-Pierre, S., Savard, R., and Boulanger, Y. (1997). Solution structure of neuropeptide tyrosine 13-36, a Y2 receptor agonist, as determined by NMR. Eur. J. Biochem. 246, 780-785.
36. Lam, E. W., Francis, R. E., and Petkovic, M. (2006). FOXO transcription factors: key regulators of cell fate. Biochem. Soc. Trans. 34, 722-726.
37. Makarov, V. G., Makarova, M. N., Sto-laschyck, N. V., Wikman, G., and Panossian, A. (2007). Potential Use of Plant Adaptogen in Age Related Disorders, Celebration of the Centennial Birth of Hans Selye. Budapest. Hungary: Cell Stress and Chaperones, 242.
38. Martel, J. C., Fournier, A., St-Pierre, S., Dumont, Y., Forest, M., and Quirion, R. (1990). Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neu-ropeptide Y receptors. Mol. Pharma col. 38, 494-502.
39. Mattioli, L., Funari, C., and Per-fumi, M. (2009). Effects of Rhodiola rosea L. extract on behavioural and physiological alterations induced by chronic mild stress in female rats. J. Psychopharmacol. 23, 130-142.
40. Morales-Medina, J. C., Dumont, Y., Benoit, C. E., Bastianetto, S., Flo-res, G., Fournier, A., and Quirion, R. (2012). Role of neuropeptide Y Y(1) and Y(2) receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neurophar-macology 62, 200-208.
41. Morales-Medina, J. C., Dumont, Y., and Quirion, R. (2010). A possible role of neuropeptide Y in depression and stress. Brain Res. 1314, 194-205.
42. Morgan, C. A. III, Wang, S., Rasmus-son, A., Hazlett, G., Anderson, G., and Charney, D. S. (2001). Relationship among plasma cortisol, cat-echolamines, neuropeptide Y, and human performance during exposure to uncontrollable stress. Psycho-som. Med. 63, 412-422.
43. Morgan, C. A. III, Wang, S., South-wick, S. M., Rasmusson, A., Hazlett, G., Hauger, R. L., and Charney, D. S. (2000). Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 47, 902-909.
44. Morris, M. J., Russell, A. E., Kapoor, V., Cain, M. D., Elliott, J. M., West, M. J., Wing, L. M., and Chalmers, J. P. (1986). Increases in plasma neu-ropeptide Y concentrations during sympathetic activation in man. J. Auton. Nerv. Syst. 17, 143-149.
45. Narimanian, M., Badalyan, M., Panosyan, V., Gabrielyan, E., Panossian, A., Wikman, G., and Wagner, H. (2005). Impact of Chisan (ADAPT-232) on the quality-of-life and its efficacy as an adjuvant in the treatment of acute non-specific pneumonia. Phytomedicine 12, 723-729.
46. Nergardh, R., Ammar, A., Brodin, U., Bergstrom, J., Scheurink, A., and Sodersten, P. (2007). Neuropep-tide Y facilitates activity-based-anorexia. Psychoneuroendocrinology 32, 493-502.
47. Olsson, E. M., von Scheele, B., and Panossian, A. G. (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 75, 105-112.
48. Pages, N., Orosco, M., Fournier, G., Rouch, C., Hafi, A., Gourch, A., Comoy, E., and Bohuon, C. (1991). The effects of chronic administration of morphine on the levels of brain and adrenal catecholamines and neuropeptide Y in rats. Gen. Pharmacol. 22, 943-947.
49. Panossian, A. (2003). Adaptogens: tonic herbs for fatigue and stress. Altern. Compement. Therap. 9, 327-332.
50. Panossian, A., Hambartsumyan, M., Hovanissian, A., Gabrielyan, E., and Wilkman, G. (2007). The adapto-gens Rhodiola and Schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol. Drug Targets Instights 1, 39-54.
51. Panossian, A., and Wagner, H. (2005). Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother. Res. 19, 819-838.
52. Panossian, A., and Wikman, G. (2008). Pharmacology of Schisandra chinen-sis Bail.: an overview of Russian research and uses in medicine. J. Ethnopharmacol. 118, 183-212.
53. Panossian, A., and Wikman, G. (2009). Evidence-based efficacy of adap-togens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr. Clin. Pharmacol. 4, 198-219.
54. Panossian, A., and Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals 3, 188-224.
55. Panossian, A., Wikman, G., Kaur, P., and Asea, A. (2009). Adaptogens exert a stress-protective effect by modulation of expression of molecular chaperones. Phytomedicine 16, 617-622.
56. Panossian, A., Wikman, G., Kaur, P., and Asea, A. (2010). "Molecular chap-erones as mediators of stress protective effect of plant adaptogens," in Heat Shock Proteins and Whole Body Physiology, eds A. Asea and B. K. Pedersen (Dordrecht: Springer), 351-364.
57. Panossian, A., Wikman, G., and Sarris, J. (2011). Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 17, 481-493.
58. Panossian, A., Wikman, G., and Wagner, H. (1999). Plant adaptogens. III. Earlier and more recent aspects and concepts on their mode of action. Phytomedicine 6, 287-300.
59. Rasmusson, A. M., Schnurr, P. P., Zukowska, Z., Scioli, E., and Forman, D. E. (2010). Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome. Exp. Biol. Med. (May-wood) 235, 1150-1162.
60. Redrobe, J. P., Dumont, Y., Fournier, A., and Quirion, R. (2002). The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 26, 615-624.
61. Redrobe, J. P., Dumont, Y., St-Pierre, J. A., and Quirion, R. (1999). Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 848, 153-166.
62. Samuelsson, G., and Bohlin, L. (2009). Drugs of Natural Origin: A Treatise of Pharmacognosy, 6th Edn. Stockholm: Swedish Academy of Phramaceuti-cal Sciences.
63. Sederholm, F., Ammar, A. A., and Soder-sten, P. (2002). Intake inhibition by NPY: role of appetitive inges-tive behavior and aversion. Physiol. Behav. 75, 567-575.
64. Sedlackova, D., Kopeckova, J., Pape-zova, H., Vybiral, S., Kvasnickova, H., Hill, M., and Nedvidkova, J. (2011). Changes of plasma obestatin, ghre-lin and NPY in anorexia and bulimia nervosa patients before and after a high-carbohydrate breakfast. Phys-iol. Res. 60, 165-173.
65. Senf, S. M., Dodd, S. L., and Judge, A. R. (2010). FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am. J. Physiol. Cell Physiol. 298, C38-C45.
66. Small, C. J., Morgan, D. G., Meeran, K., Heath, M. M., Gunn, I., Edwards, C. M., Gardiner, J., Taylor, G. M., Hurley, J. D., Rossi, M., Goldstone, A. P., O'Shea, D., Smith, D. M., Ghatei, M. A., and Bloom, S. R. (1997). Peptide analogue studies of the hypothala-mic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. Proc. Natl. Acad. Sci. U.S.A. 94, 11686-11691.
67. Smialowska, M., Wieronska, J. M., Domin, H.,and Zieba, B. (2007).The effect of intrahippocampal injection of group II and III meto-botropic glutamate receptor agonists on anxiety; the role of neuropep-tide Y. Neuropsychopharmacology 32, 1242-1250.
68. Stogner, K. A., and Holmes, P. V. (2000). Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats. Eur. J. Pharmacol. 387, R9-R10.
69. Stratakis, C. A., and Chrousos, G. P. (1995). Neuroendocrinology and pathophysiology of the stress system. Ann. N. Y. Acad. Sci. 771, 1-18.
70. Tatemoto, K., Carlquist, M., and Mutt, V. (1982). Neuropeptide Y a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296, 659-660.
71. Trent, N. L., and Menard, J. L. (2011). Infusions of neuropeptide Y into the lateral septum reduce anxiety-related behaviors in the rat. Pharmacol. Biochem. Behav. 99, 580-590.
72. Ubink, R., Calza, L., and Hokfelt, T. (2003). 'Neuro'-peptides in glia: focus on NPY and galanin. Trends Neurosci. 26, 604-609.
73. Wahlestedt, C., and Reis, D. J. (1993). Neuropeptide Y-related peptides and their receptors - are the receptors potential therapeutic drug targets? Annu. Rev. Pharmacol. Toxicol. 33, 309-352.
74. Wiegant, F. A., Surinova, S., Ytsma, E., Langelaar-Makkinje, M., Wikman, G., and Post, J. A. (2009). Plant adap-togens increase lifespan and stress resistance in C. elegans. Biogerontology 10, 27-42.
75. Woldbye, D. P., Klemp, K., and Mad-sen, T. M. (1998). Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors. J. Pharmacol. Exp. Ther. 284, 633-636.
76. Wu, C. (1995). Heat shock transcription factors: structure and regulation. Annu. Rev. Cell Dev. Biol. 11, 441-469.
77. Yang, L., Scott, K. A., Hyun, J., Tamashiro, K. L., Tray, N., Moran, T. H., and Bi, S. (2009). Role of dor-somedial hypothalamic neuropep-tide Y in modulating food intake and energy balance. J. Neurosci. 29, 179-190.
78. Zhong, W. D., Zeng, G. Q., Hu, J. B., Cai, Y. B., Liu, J. K., Huang, S. H., Chen, M. S., and Wei, H. A. (2003). Stimulation of neuropeptide Y on heat shock protein expression in renal vascular smooth muscle and the inhibition thereon by losartan. Zhonghua Sheng Wu Yi Xue Gong Cheng Za Zhi 83, 515-517.